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Background: Cryptococcus neoformans causes meningitis and disseminated infection in healthy individuals, but
more commonly in hosts with defective immune responses. Cell-mediated immunity is an important component of
the immune response to a great variety of infections, including yeast infections. We aimed to evaluate a specific
lymphocyte transformation assay to Cryptococcus neoformans in order to identify immunodeficiency associated to
neurocryptococcosis (NCC) as primary cause of the mycosis.
Methods: Healthy volunteers, poultry growers, and HIV-seronegative patients with neurocryptococcosis were tested
for cellular immune response. Cryptococcal meningitis was diagnosed by India ink staining of cerebrospinal fluid
and cryptococcal antigen test (Immunomycol-Inc, SP, Brazil). Isolated peripheral blood mononuclear cells were
stimulated with C. neoformans antigen, C. albicans antigen, and pokeweed mitogen. The amount of 3H-thymidine
incorporated was assessed, and the results were expressed as stimulation index (SI) and log SI, sensitivity, specificity,
and cut-off value (receiver operating characteristics curve). We applied unpaired Student t tests to compare data
and considered significant differences for p<0.05.
Results: The lymphotoxin alpha showed a low capacity with all the stimuli for classifying patients as responders
and non-responders. Lymphotoxin alpha stimulated by heated-killed antigen from patients with
neurocryptococcosis was not affected by TCD4+ cell count, and the intensity of response did not correlate with the
clinical evolution of neurocryptococcosis.
Conclusion: Response to lymphocyte transformation assay should be analyzed based on a normal range and using
more than one stimulator. The use of a cut-off value to classify patients with neurocryptococcosis is inadequate.
Statistical analysis should be based on the log transformation of SI. A more purified antigen for evaluating specific
response to C. neoformans is needed.
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Cryptococcus neoformans causes meningitis and disse-
minated infection in healthy individuals, but more
commonly in hosts with defective immune responses
[1-3]. Cell-mediated immunity is an important compo-
nent of the immune response to a great variety of
infections, including yeast infections. Hence, impaired
T-cell activation can increase the susceptibility to fun-
gal pathogens like C. neoformans [4-6]. Graybill and
Alford (1974) [7] observed reduced delayed-type hyper-
sensitivity reactions against fungi like Histoplasma cap-
sulatum and Candida albicans, as well as against a
mitogen, in HIVseronegative patients recovered from
cryptococcal disease, suggesting a decreased cellular re-
sponse in these patients.
Lymphocyte transformation assay potentially offers a
sensitive indicator for several conditions involving
lymphocyte dysfunction due, for instance, to immuno-
logic deficiency [8]. A decreased T-cell proliferative re-
sponse to a mitogen, such as pokeweed (POKEWEED
MITOGEN) or phytohemagglutinin (PHA), or to recall
antigens, such as C. albicans or tetanus toxoid, could be
an early marker of immune dysfunction in HIV-infected
patients [9]. Additionally, lymphotoxin alpha could also
be useful for evaluating sensitization to metals [10] in al-
lergic diseases, for testing vaccine efficacy [11], and for
assessing the effect of new immunostimulatory drugs
[12].
There is, however, no general agreement among inves-
tigators on how to express data and to define, consider-
ing methodological variations, depressed or activated
T-cell responses [13-17].
The clinical utility of lymphotoxin alpha depends on
the skills of the clinical immunologist in interpreting
data and on the establishment by the laboratory of a
normal range [18]. In assays with 3H-thymidine incorp-
oration as a marker of cell proliferation, the most usual
way to represent the results is to calculate the difference
between counts per minute (cpm) of the stimulated cells
and the cpm of the non-stimulated cells (delymphotoxin
alpha cpm). Also, the stimulation index (SI), the ratio of
stimulated cells cpm and nonstimulated cells cpm, has
been used.
This study was undertaken to evaluate a specific
lymphocyte transformation assay to Cryptococcus neofor-
mans in order to identify immunodeficiency associated
to NCC as primary cause of the mycosis.
Methods
The study was conducted between August 2004 and
December 2006 and comprised 3 groups: a) 45 healthy
volunteers; b) 24 poultry growers from Jumirim, SP, Bra-
zil, who were individuals occupationally exposed to C.
neoformans; and c) 25 HIV-seronegative patients withNCC. All patients with NCC were tested during their
first or second episode of cryptococcal meningitis.
Informed consent was obtained regarding blood samples
from patients and control subjects, consent was obtained
from parents for samples taken from babies. Patients re-
ceiving immunosuppressive medication or previously
defined as immunodeficient and presenting with tumors
or other infectious diseases were excluded. Age, gender,
and T-lymphocyte counts of each group are presented in
Table 1. For controls, we used blood samples from
healthy volunteers and from healthy newborns. Three
cord blood samples were obtained immediately after
birth from healthy babies born at Maternal, Amparo,
Brazil. All work procedures were approved by the Ethics
Committee in Research of Instituto Emílio Ribas (proto-
col number 246/08) and followed Resolution 196/96 of
the National Health Council of October 10, 1996.Cryptococcal meningitis diagnosis
Cryptococcal meningitis was diagnosed by India ink
staining of cerebrospinal fluid and cryptococcal antigen
test (Immunomycol-Inc, SP, Brazil). Cryptococcus neofor-
mans was identified by glossy, mucoid, and cream-
colored colonies [19] cultured on Agar Niger and Agar
Sabouraud (3 days at room temperature). Species con-
firmation was performed by positive urease test [19].
The protocol was approved by the Institutional Review
Board of “Universidade de São Paulo” Medical School
and of “Instituto Emílio Ribas.”Procedures
Lymphocyte transformation assay stimulated by
POKEWEED MITOGEN, CMA, and C. neoformans
antigen was established in all groups, according to the
following steps: Preparation of antigens: Noncapsu-
lated cells of C. neoformans serogroups A, B, C, and D
were cultured separately on Sabouraud dextrose agar at
25°C for 3 days. Cells were harvested, mixed, and used
to prepare heat-killed antigen (KAg) and soluble cell
wall antigen (SAg). In order to prepare SAg, mixed
yeasts were disrupted with glass powder, the final pellet
was re-suspended in PBS 0.1 M (pH 7.2), and 10 mM
protease inhibitor (methyl-phenyl-sulphonyl fluoride)
was added. Yeast mixtures were incubated at 4°C for 48
hours. The suspension was centrifuged 3 times at 8000
rpm for 20 minutes. Supernatant was stored at −20°C
until use. Protein concentration was determined by the
Biuret method (protein concentration of pure antigen =
420 μg/mL). Heated-killed antigen mixed yeasts were
suspended in PBS 0.1 M (pH 7.2) and heated at 121°C
for 15 minutes. Cell concentrations were determined by
hemocytometer (180 x 106 yeasts/mL).
Table 1 Characterization of studied groups: number of studied individuals, median age, sex distribution, median of
total lymphocytes, LTCD4+ and LTCD8+
Group n Lymphocyte
cell/mL
LTCD4+
cell/mL
LTCD8+
cell/mL
Age
(years)
Sex distribution
male female
Control individuals 45 1800 (1300–4390) 959 (556–2577) 497 (249–725) 26.5 (15–48) 26 19
Poultry growers 24 1720 (1180–3500) 828 (495–1380) 398 (167–763) 50.5 (15–75) 10 14
NCC patients 25 1580 (700–4390) 668 (15–1808) 459 (113–1137) 31.7 (15–60) 19 6
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Peripheral blood mononuclear cell (PBMC) from healthy
volunteers and newborn cord blood cells were isolated
by Ficoll-Hypaque density gradient (20 mL). The cells
were centrifuged, washed 3 times at 4°C in NaCl
(0.85%), re-suspended in RPMI 1640 medium, and sup-
plemented with 10% AB human serum. The cellular con-
centration was adjusted to 2 × 106 cells/mL. Triplicates
of each of the following stimulators were used: poke-
weed mitogen as positive control, and Candida meta-
bolic antigen (CMA) as heterologous antigen. A
triplicate of wells without stimulation was used as a
negative control. The cells were then incubated in 96-
well microplates in a 5% CO2 atmosphere at 37°C for 6
days. Eighteen hours before the final evaluation, 20 μL
of 3H-thymidine were added to each well (1 μCi). On
the sixth day, cultures were harvested on a glass fiber fil-
ter with a cell harvester device and prepared for count-
ing. The amount of 3H-thymidine incorporated into
DNA was assessed by liquid scintillation (Wallac Beta
Plate equipment). Results were calculated as stimulation
index (SI: mean of antigen-stimulated cells cpm divided
by non-stimulated cells cpm). Log SI Cord blood cells
were evaluated in order to test the mitogenic effect of
the antigens.
PBMC (30 mL) from all groups were isolated, and the
lymphotoxin alpha was performed as described previ-
ously. The following stimulators were used: KAg (4.5
×106 yeasts/mL), pokeweed mitogen (5 μg/mL), and
CMA (5 μg/mL). In order to classify patients as respon-
ders and non-responders to stimulators, we applied an
ROC (receiver operating characteristics) curve to estab-
lish a cut-off value and the 5th to 95th percentile range
(as the normal range). We also calculated the specificity
and sensitivity of lymphotoxin alpha using Win Episcope
2.0 software.
Statistical analysis
Medians were compared, and unpaired Student t tests
using a statistical software program (GraphPad Prisma
3.0) were used to analyze the lymphotoxin alpha. A P
value less than 0.05 was applied to define a significant
difference. Pearson’s coefficient was used to evaluate the
correlation between lymphotoxin alpha stimulated by
CMA and KAg for all groups studied. The 5th to 95thpercentile range of lymphotoxin alpha was obtained by
Sigma Stat software.
Results
Standardization of lymphocyte transformation assay to
C. neoformans antigen
In an initial experiment (data not shown), we investi-
gated the immunogenicity of SAg and KAg. For this
purpose, PBMC from 3 individuals (healthy volunteers)
and 2 HIV-seronegative patients with NCC were stimu-
lated in vitro with several concentrations of SAg [4.2
μg/mL (dil. 1/100), 0.84 μg/mL (dil. 1/500), 0.42 μg/mL
(dil. 1/1.000), 0.084 μg/mL (dil. 1/5000), 0.042 μg/mL
(dil. 1/10000)] and KAg [18 x106 yeasts/mL (dil. 1/10),
1.8 x106 yeasts/ mL (dil. 1/100), 0.36 x106 yeasts/ mL
(dil. 1/500), 0.180 x106 yeasts/mL (dil. 1/1000), 0.018 x
106 yeasts/mL (dil. 1/10000)]. Both antigens were im-
munogenic, and the best responses were obtained with
4.2 μg/mL and 0.84 μg/mL for SAg, and 18 x106 yeasts/
mL (dil. 1/10) and 1.8 x106 yeasts/mL (dil. 1/100) for
KAg. Heated-killed antigen was more immunogenic than
SAg, regardless of the applied concentration or the
method used to evaluate the results (Figure 1). The
lympho-proliferations detected with KAg dilutions 1/10,
1/40, and 1/100 were similar. A 1/100 dilution of SAg
produced higher lymphocyte stimulation than a dilution
of 1/500, and SAg elicited less lymphocyte proliferation
than any concentration assayed of KAg (Figure 1). Data
were evaluated as raw cpm and Δ cpm (data not shown),
and there was no significant difference in SI of the results,
even after logarithmic transformation (Figure 1). Table 2
shows P values from statistical analysis of lymphotoxin
alpha obtained after stimulation by KAg and SAg of
PBMC from the control group (Mann–Whitney test).
Determination of receiver operating characteristics (ROC)
curve, sensitivity, specificity, cut-off value, and 5th to 95th
percentile range of the lymphotoxin alpha
We analyzed the capability of the lymphotoxin alpha to
classify patients with NCC as responders and non-
responders by means of the cut-off value established by
an ROC curve and the normal range (5–95 percentile).
The lymphotoxin alpha showed a low capacity with all
the stimuli for classifying patients as responders and
non-responders. Maximum area obtained from ROC
Figure 1 Standardization of lymphoproliferative response to C. neoformans antigens (KAg and SAg) from healthy individuals (n = 45).
Results were calculated as: A) Stimulation index and B) log SI.
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(96%) was observed with pokeweed mitogen stimulation,
and the maximum specificity (82%) was obtained with
KAg stimulation. The lymphotoxin alpha performed
with CMA showed lower sensitivity and specificity com-
pared with pokeweed mitogen or KAg. The cut-off value
(SI) obtained from the ROC curve varied for different
stimuli: 15 (KAg), 23 (pokeweed mitogen), and 12
(CMA). Applying the established cut-off value, patients
with NCC classified as responders were: a) 10/25 (KAg),
b) 8/25 (CMA), and c) 24/25 (pokeweed mitogen).
The lymphotoxin alpha on cells from patients with
NCC was also analyzed compared with the 5th to 95th
percentile range from a healthy volunteer population
(normal range: CMA > 3.4 SI; KAg > 0.8 SI, and poke-
weed mitogen > 8.4 SI. Patients with NCC considered
responders were: a) 25/25 (KAg), b) 12/25 (CMA), and
c) 25/25 (pokeweed mitogen).
Lymphocyte transformation assay stimulated with fungal
antigen and mitogen
There was no significant difference between poultry
growers and controls in specific T-lymphocyte response
to KAg for values calculated as delymphotoxin alphaTable 2 P values from statistical analysis of lymphotoxin
alpha obtained after stimulation by KAg and SAg of
PBMC from the control group (Mann–Whitney test)
KAg 1/10 KAg 1/40 KAg 1/100
SI log SI SI log SI SI log SI
SAg 1/100 .01 .009 .001 .001 .01 .003
SAg 1/500 .001 .001 .001 .001 .001 .001cpm (data not shown) or SI (P = 0.19). However, a sig-
nificant difference was found in poultry growers com-
pared with controls when data for lymphocyte
proliferation was expressed as log SI (P = .03) (Figure 2).
Poultry growers also showed higher specific lymphocyte
response to C. albicans than controls (P = 0.004)
(Figure 2). Both groups presented similar responses to
pokeweed mitogen (P = 0.13) (Figure 2).
There was no correlation between lymphotoxin alpha
results for different fungal antigens (KAg versus CMA)
for the control group, regardless of how data were calcu-
lated (r =0.01 for delymphotoxin alpha cpm and r =
−0.13 for SI). However, for poultry growers, there was a
stronger correlation of the lymphotoxin alpha results for
different fungal antigens when data were calculated as
delymphotoxin alpha cpm and SI (r = 0.81).
Specific lymphocyte responses to cryptococcal antigen
(KAg) by PBMC from patients with NCC, expressed by
SI, log SI, or delymphotoxin alpha cpm (data not
shown), were similar (P > .5) to responses by controls
and poultry growers (Figure 2). Specific lymphocyte re-
sponse to C albicans antigen (Figure 2) was lower when
PBMC from patients with NCC and controls compared
with poultry growers. Patients with NCC, farmers, and
controls had similar responses (without statistical differ-
ence) to pokeweed mitogen (Figure 2). For lymphotoxin
alpha of PBMC from patients with NCC, there was a
medium correlation of CMA and KAg when data were
calculated as SI (r = 0.7).
Discussion
Clinical observations suggest that intact cellular immune
response is a major determinant in the outcome of
Figure 2 Lymphoproliferative response to C. neoformans antigen (A and B) to Candida albicans antigen (C and D) and to pokeweed
mitogen (E and F) from control group (nonoccupational exposure individuals, n = 45), poultry growers (occupational exposure
individuals, n = 24) and neurocryptococcosis (NCC) patients (n = 22). Results were expressed as: stimulation index (SI) (A, C and E) and log
SI (B, D and F).
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mechanisms like antibodies to Cryptococcus antigens
[22], antibody-dependent cell cytotoxicity [23], comple-
ment [24-27], and natural killer cells [27] also have a
role in eliminating organisms. However, the frequency
and severity of neurocryptococcosis and disseminated
infection caused by C. neoformans in patients with
AIDS clearly emphasizes the requirement for a T-
cell–mediated immune response to this fungus [28,29].
An adequate antigen capable of eliciting lymphocyte
activation in vitro and available for investigation of C.
neoformans–specific T-cell response has not yet been
identified; nor has the best approach for interpretingresults been defined. The classification of a patient as re-
sponder or non-responder to an antigen could be useful
to the clinical immunologist for classifying patients as
immunocompetent or immunodeficient. We have stud-
ied lymphoproliferation to two different antigens: soluble
cell wall antigen (SAg) and heat-killed yeast antigen
(KAg). Since the capsular polysaccharide itself, a known
virulence factor present in the intact C. neoformans, can
suppress the lymphocyte proliferation [30], we prepared
antigens with non-encapsulated yeasts. Both tested
antigens were immunogenic to PBMC from healthy
volunteers, but heat-killed yeast (KAg) was more im-
munogenic than soluble cell wall antigen (SAg).
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fect of cell wall antigen from C. neoformans to PBMC,
we investigated whether the observed lymphocyte stimu-
lation could be nonspecific (mitogenic effect). For this
purpose, PBMC from cord blood were stimulated with
both antigens (data not shown). Neither KAg nor SAg
elicited stimulation of the cord blood cells. Therefore,
the lymphoproliferation from healthy volunteers could
be specific to C. neoformans.
Our results were similar to those observed by Miller
and Puck (1984) [13], demonstrating that normal indivi-
duals (volunteers) without continuous exposure to C.
neoformans had significant specific lymphoproliferative
response to fungal antigen. Since C. neoformans is com-
mon in the environment [32], all individuals, even the
healthy ones, could be exposed to the fungus. As
reported, the volunteers not occupationally exposed are
also responsive to fungal antigens. The environment is
the only contaminating source, which exposed them
daily (subjects exposed to occupational contact were
excluded).
Based on the Miller and Puck study [13] and accord-
ing to our findings, Cryptococo exposure occurs in the
environment regardless of occupational exposure. In our
study we pointed out that newborns do not respond to
fungus and that the antigen used in the assays does not
provide mitogenic effect. Therefore, subjects with no oc-
cupational exposure that respond to the fungi are related
to a consequence of environmental exposure, as sug-
gested by Miller and Puck [13].
Since contaminated feces and pigeon droppings are
major sources of natural exposure to C. neoformans
[33,34], we investigated the effect of this continuous ex-
posure to specific lymphocyte response to C. neoformans
antigen among poultry growers. They presented an
increased lymphocyte response to C. neoformans antigen
compared with non-exposed volunteers. It is interesting
to note that this greater response could be only observed
when data were analyzed after logarithmic transform-
ation of stimulation index (log SI). When the data were
calculated as delta cpm (data not shown) or SI, this stat-
istical difference was not observed.
It is interesting to note that lymphoproliferative re-
sponse to CMA antigen of peripheral blood mono-
nuclear cell from poultry growers was higher than
controls, regardless of the method used for data calcula-
tion. A possible explanation is that poultry growers are
continuously exposed to C. neoformans (more than 10
years), increasing sensitized lymphocytes, which cross-
react with C albicans antigen. Pietrella et al. (2002) [35]
showed that immunized mice with mannoprotein from
C. neoformans developed delayed-type hypersensitivity
(DTH), a Th1 response, against lethal challenge with
mannoprotein from C. albicans. As a matter of fact,there was a stronger and a moderate correlation (r =
0.81 and r = 0.7, respectively) of lymphoproliferative re-
sponse by PBMC stimulated with CMA and KAg from
poultry growers and patients with NCC, while PBMC
from controls showed a poor correlation. Our data, as
demonstrated by Pietrella et al. (2002) [35], also suggest
a cross-reaction between epitopes of C albicans and C.
neoformans in the T-cell response. On the other hand,
the elevated lymphoproliferative response from poultry
growers could be interpreted as a simple consequence of
a better capability to respond or even a greater clonal
expansion determined by continuously exposure to
fungus.
In order to identify nonresponsive individuals or im-
pairment of specific in vitro response to C. neoformans,
the assay was also applied to HIV-seronegative patients
with NCC. The patients’ specific lymphocyte response to
KAg and pokeweed mitogen was not different from that
observed with other groups (poultry growers or healthy
volunteers), but it was lower for CMA, when compared
with poultry growers. Our results were in accordance
with those obtained by Levitz and North (1997) [36],
who demonstrated that kinetics and magnitude of cellu-
lar immune response to C. neoformans antigen from
patients and control group (without continuous expos-
ure) are quite similar.
If we consider, as standardized in our laboratory, the
5th percentile of SI as the normal range cut-off value for
classifying individuals as responders or nonresponders
to the antigens (KAg and mitogen), 100% of patients
could be considered responders, but only 50% were re-
sponsive to CMA. On the other hand, if we use the
ROC analysis to obtain a cut-off value, the number of
responders and nonresponders is quite different, mainly
because the cut-off values were much higher than the
5th percentile of S.I. The ROC area, whose value repre-
sents the capability of the assay to discriminate subjects
into two categories, showed us that the lymphotoxin
alpha to C. neoformans antigen (like KAg) is a method
that should not be used for diagnostic purposes, since
this kind of method should present a ROC area of
around 100%, high specificity, and high sensitivity.
Lymphocyte transformation assay stimulated by KAg
from patients with NCC was not affected by TCD4+ cell
count, and the intensity of response did not correlate
with the clinical evolution of neurocryptococcosis. Cured
patients without neurological sequelae presented a SI to
KAg varying from 0.87 to 71, while patients who devel-
oped neurological sequelae or died presented high levels
of specific lymphocyte response to KAg (SI, 1.27 - 368).
It might be expected that responses to short, relatively
simple antigens such as synthetic peptides might indi-
cate more precisely the difference between responders
and nonresponders than the responses to complex
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responding cell clones would be much lower [33]. In
addition, our data have been taken from a study of an
uncommon disease caused by a fungus to which a great
proportion of the population has been exposed.
It is important to mention that the diagnosis applied
to the NCC patients is only directed to the diagnosis of
fungal disease [37]. Although many Cryptococcosis cases
are still diagnosed in immunocompetent individuals [38]
the clinical management of patients with NCC is that
cryptococcosis is an opportunistic disease. The evalu-
ation of primary immunodeficiency after diagnosis is not
indicated, it is not mentioned other immunological tech-
niques (serological or cellular) to a diagnosis of the dis-
ease and its association with immunodeficiency.
Our results led us to conclude that specific lympho-
proliferative response should be presented as SI, rather
than raw cpm or delta cpm. Nevertheless, the compari-
son between two groups should be done by SI log trans-
formation, which decreases variance. The use of mitogen
stimulation reflects, with high sensitivity, nonspecific T-
cell response capability, which was positive in all
patients with NCC. The evaluated patients may not be
classified as non-responders to C. neoformans by lym-
phoproliferative response assay. Considering all the
results, lymphoproliferation assay applied to C. neofor-
mans associated immunodeficiency diagnoses should be
considered as a screening assay only. Furthermore, neu-
rocryptococcosis is a disorder which has received large
attention recently [39,40].
Conclusions
Our data suggest that: 1) Analysis of lymphotoxin alpha
response should be based on a normal range and ana-
lyzed using more than one stimulator; 2) The use of a
cut-off value to classify patients with NCC as responders
or non-responders to fungal antigens and mitogen is in-
adequate. We recommend the application of lympho-
toxin alpha with another purified antigen to better
evaluate a patient with NCC. It is advisable to use both
stimuli to have a better overview of T-lymphocyte
function.
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